About the Company
Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MLND News
Global Congenital Adrenal Hyperplasia Treatment Market Poised for Significant Growth, Reaching US$ 892 Million by 2033
Congenital Adrenal Hyperplasia Treatment Market is anticipated to soar to US$ 892 million by 2033 projecting a CAGR of 8.1%.
Millendo Therapeutics (NASDAQ:MLND) Will Have To Spend Its Cash Wisely
Given this risk, we thought we'd take a look at whether Millendo Therapeutics (NASDAQ:MLND) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the ...
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
Inc., Millendo Therapeutics Inc., and the Biotechnology Innovation Organization (BIO). Mr. Dable previously led Acceleron Pharma, Inc. as President and Chief Executive Officer, eventually facilitating ...
Tempest and Millendo Announce Stockholder Approval of Merger
About Millendo Therapeutics, Inc. Millendo Therapeutics is a biopharmaceutical company previously primarily focused on developing novel treatments for endocrine diseases where current therapies do ...
Joshua Makower's Net Worth
Joshua Makower has an estimated net worth of $231 Million. This is based on reported shares across multiple companies, which include Desktop Metal, Inc., Cascadian Therapeutics, Inc., Nkarta, Inc ...
FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin ...
ATXS Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Esperion Therapeutics, Inc. (ESPR)
and MUNICH, Germany, March 22, 2024 (GLOBE NEWSWIRE) -- Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) and Esperion Therapeutics, Inc. jointly announced today, that the Committ In ...
TG Therapeutics Inc TGTX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
CytomX Therapeutics, Inc. (CTMX)
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the ...
Omega Therapeutics Inc OMGA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Loading the latest forecasts...